Home
HURA
HURA News

Latest TuHURA Biosciences Inc. Common Stock (HURA) News on April 3, 2025

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a day ago

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

PR Newswire

2 days ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

ACCESS Newswire

23 days ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

ACCESS Newswire

24 days ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

ACCESS Newswire

a month ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

HURA: Initiating an Immune Response

Zacks Small Cap Research

2 months ago

HURA: Initiating an Immune Response

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

Simply Wall St.

3 months ago

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

ACCESSWIRE

4 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

ACCESSWIRE

4 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ACCESSWIRE

5 months ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

ACCESSWIRE

5 months ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Share on Social Networks: